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ABSTRACT: The evaluation of novel photosensitizers (PSs) for
photodynamic therapy (PDT) is difficult due to the limitations of
two-dimensional cell culture and multiple parameters (dose, light
intensity, uptake time), which complicate progression to in vivo
experiments and clinical translation. Three-dimensional (3D) cell
culture models like multicellular cancer tumor spheroids (MCTS)
show great similarities to in vivo avascular tumor conditions,
improving the speed and accuracy of screening novel compounds
with various treatment combinations. In this study, we utilize
C8161 human melanoma spheroids to screen PDT treatment
combinations using protoporphyrin IX (PpIX) and drug-loaded
carbon dot (CD) conjugates PpIX-CD and PpIX@CD at ultralow
fluence values (<10 J/cm2). Conjugates show equivalent light-induced damage to PpIX from 1 μg/mL with significantly less dark
cytotoxicity up to 72 h after exposure, shown by LDH release and dsDNA content. Fractionated treatments, carried out by dividing
light exposure with 24 h intervals, demonstrate an enhanced PDT effect compared to single exposure at equal concentrations. Light
sheet fluorescence microscopy combined with live/dead staining demonstrates that spheroids sustain extensive damage after PDT,
with PpIX and PpIX-CD showing improved uptake compared to PpIX@CD. We show that PDT parameter screening can be carried
out using a low-cost and convenient combination of assays to improve the efficiency of evaluating novel compounds.
KEYWORDS: photodynamic therapy, light fractionation, cancer spheroids, 3D cell culture, protoporphyrin IX, nanoparticles, carbon dots,
light sheet fluorescence microscopy
■ INTRODUCTION
Photodynamic therapy (PDT) is an FDA-approved non-
invasive cancer treatment that benefits from high site
specificity, low cost, adaptability, and controlled dosimetry1
Photosensitizers (PSs) are compounds, which are capable of
producing reactive oxygen species, including singlet oxygen
(1O2), when irradiated with a specific wavelength of light,
leading to internal damage and ultimately cell death.2
However, many PSs cause off-target toxicity, have low water
solubility, and rapidly undergo photobleaching, limiting their
efficiency in vivo.3 In the 1980s, first generation PSs composed
of porphyrins such as hematoporphyrin and porfimer sodium
showed initial success but limited clinical use due to their
unsuitable activation wavelengths and prolonged sensitization4
Second generation PSs improved their function through
chemical modifications, typically by altering functional groups.
Other molecules were also investigated, including metal-
loporphyrins, phthalocyanines, chlorins, and dipyrromethenes5
In recent years, PS development has expanded beyond
modifications to the molecular structure and synthesis of new
compounds. The use of carriers such as antibodies,6 small
targeting molecules7 metal-organic frameworks8 and nano-
particles,9 has seen increased research interest, though testing
of these novel agents is a complex task as there are a multitude
of parameters to evaluate, such as light sources, irradiance,
drug concentration, uptake time, and partial oxygen
pressure.10,11 Among these carriers are carbon dots (CDs),
highly biocompatible nanoparticles with tunable photo-
luminescence and surface chemistry, which have been
previously used for PDT.12
Currently, in vivo tumor xenograft mouse models are the
gold standard for PDT evaluation, often used early in the
translational process with PS administered through subcuta-
neous injection or topical application; human tumor xenografts
have also been explored for PS evaluation but are susceptible
to infections. Animal models have been widely successful and
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provide valuable insight as in the preclinical evaluation of novel
compounds13 However, they are hindered by strict regulatory
controls, and the evaluation of multiple PDT treatment
combinations is increasingly more difficult as more parameters
are introduced, further complicating treatment standardization.
Additionally, various PDT strategies have shown conflicting
results clinically with standard PSs, such as the use of low-
fluence light sources and fractionationa clinical practice
whereby the total light dose is divided into two or more
exposures separated by a period in the dark.14−16
Thus, there is an urgent need for better models of PDT for
in vitro PS evaluation prior to in vivo testing in animal models.
Cell monolayers have been shown to be inefficient for drug
evaluation as conditions such as diffusion rates, protein
expression, and cell−cell interactions vary compared to in
vivo tissue.17 Three-dimensional (3D) cell culture models are
key to understanding tumor biology and developing new
strategies for drug delivery, which consider the tissue
architecture and microenvironment. There are various
established models used for drug screening, which include
organotypic tissue cultures from patients,18 scaffolds for tissue
engineering,19 organoids,20 and spheroids21
Multicellular tumor spheroids (MCTS) are well-established
3D cell models, which resemble tumors morphologically and
biologically. Spheroids can be grown using a variety of
immortalized cell lines or patient-derived tissue samples.22
Their growth can be stimulated by preventing cells from
attaching to a suitable surface, which promotes the formation
of cell−cell interactions, production of extracellular matrix, and
compaction. In turn, this leads to the formation of biologically
relevant cell layers: an outer layer with rapidly proliferating
cells, an intermediate layer with cells in a state of quiescence,
and an inner necrotic layer caused by hypoxia and nutrient
deficiency.23 Spheroids have demonstrated greater similarity to
responses from in vivo tumors compared to cell monolayers,
showing higher drug resistance, cell−cell interactions, and
heterogeneous uptake, making them valuable tools for in vitro
evaluation of novel compounds.24
Although PDT is limited by hypoxic inner regions, which
lead to inefficient diffusion and the development of necrotic
cores, spheroids have seen increasingly more research interest
for PDT evaluation.25 In particular, their cost-effectiveness,
adaptability, ease of production, and similarities to in vivo
tumors make them ideal for PDT parameter screening in
comparison to cell monolayers.26 Spheroid size is directly
linked to drug resistance, with larger (500 μm) spheroids
showing up to a 22-fold increase in drug resistance compared
to cell monolayers with PDT.27 Therefore, identifying an
appropriate phase of spheroid development is crucial for
evaluating drug phototoxicity. The three-dimensional structure
of spheroids has been shown to influence reagent diffusion and
drug uptake depending on a multitude of factors such as
spheroids’ size, cell type, and phase of the cell cycle, leading to
poor reproducibility.28 This significantly affects drug and
nanoparticle distribution, as they typically rely on concen-
tration gradients.29
In this study, we present an in vitro 3D cell culture cancer
spheroid model for evaluating PDT parameters for novel
compounds, which combines biological assays and morpho-
logical assessment through microscopy. Our primary aim was
to demonstrate the effectiveness of parameter screening using
the combination of biological assays and microscopy. We
demonstrate key differences in spheroids at 24−72 h after PDT
treatment using previously characterized carbon dot (CD)-
protoporphyrin IX conjugates PpIX-CD and PpIX@CD.10
Additionally, fractionated treatments showed improved PDT-
induced damage compared to single light exposures. Light
sheet fluorescence microscopy was used to observe the drug
uptake and morphological changes associated with photo-
toxicity. In summary, the combination of biological assays and
microscopy improved the accuracy of parameter prediction in
multicellular cancer spheroids compared to monolayer cell
culture models while maintaining low cost, biological
relevance, and ease of use.
■ EXPERIMENTAL SECTION
Materials. All chemicals were acquired from Sigma-Aldrich
(United Kingdom) and used as received unless otherwise stated.
Dulbecco’s modified Eagle’s medium (DMEM, high glucose),
Dulbecco’s modified Eagle’s medium (DMEM, high glucose, without
phenol red), fetal bovine serum (FBS), Quant-iT PicoGreen dsDNA
quantification kit, Pierce LDH cytotoxicity assay kit, LIVE/DEAD
Viability/Cytotoxicity Kit for mammalian cells, and trypsin-EDTA
were obtained from Thermo Fisher (United Kingdom). Syringe filters
with a 0.2 μm pore size were acquired from Sarstedt (United
Kingdom), and 1 kDa MWCO, 6.4 mL/cm dialysis tubing was
acquired from Spectrum Labs. Septa steel ring caps and 35 mL glass
reaction vessels were obtained from CEM Corporation (United
Kingdom). Deionized water was used for all buffers and samples in
the experiments.
Sample Preparation. Carbon dots (CDs) and CD-PS conjugates
were prepared using a previously described protocol.5 Briefly, CDs
were synthesized via the microwave pyrolysis of citric acid or sucrose,
with ethylenediamine as a passivating agent. PpIX was added during
the microwave synthesis to produce S-guest embedded conjugates
(PpIX@CD). Amide cross-linking was used to bind CDs and PpIX,
obtaining cross-linked PpIX-CD. Conjugates were further processed
by centrifuging at 5000 rpm for 30 min and dialyzing the solution
using a 1 kDa molecular weight cutoff (MWCO), 6.4 mL/cm dialysis
tubing to remove excess reagents and waste products.
Multicellular Tumor Spheroid Culture. Human melanoma cells
(C8161) were cultured in phenol red-free DMEM with 10% fetal calf
serum, 1% penicillin and streptomycin, and 1% L-glutamine. C8161
cells were cultured in a T75 flask at 37 °C, 5% CO2 until around 80%
confluence. Multicellular tumor spheroids were produced utilizing
agar coating to prevent cell adhesion. A 1.5% agarose solution was
prepared with 2-hydroxyethylagarose and standard cell culture media
(DMEM). This solution was sterilized by autoclave and stored at 4
°C.
Agar-coated 96-well plates were prepared by adding 100 μL of the
agarose solution into each well and leaving it to set at room
temperature for at least 1 h. Plates were seeded with 100 μL of phenol
red-free media containing 6 × 103 cells per well and returned to the
incubator until the spheroids reached approximately 500 μm in
diameter. Growth media was changed every third day, adding 100 μL
to each well and removing an equal volume.
Photoactivation of CD-PS Conjugates. Spheroids were
subjected to single and double light exposure periods with a mounted
light-emitting diode (LED). CD-PS conjugates were first subjected to
ultrasonic processing with a Hielscher UP50H ultrasonic probe prior
to the dilution to remove aggregates and dissolved in phenol red-free
media at a concentration of 50 μg/mL, being kept refrigerated until
used. Stock solutions were placed in an ultrasonic water bath for 15
min at 37 °C. Spheroids were treated using conjugate dilutions to
achieve concentrations of 1, 5, and 10 μg/mL in a 200 μL volume.
The plates were then returned to the incubator for 2 h to allow
uptake.
A M405L2 ThorLabs mounted LED with a collimator adapter (λex
= 405 nm, 1500 mA output, 2.76 mW/cm2) was used to induce light-
activated toxicity. Single exposure (1LT) samples were placed under
illumination for 15, 30, and 60 min, corresponding to 2.5, 5, and 10 J/
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cm2, and subsequently returned to the incubator. Sequential light
treatments (2LT) were carried out 24 h after the first light dose using
the same methodology for 1LT. Media was removed and replaced
immediately after each light exposure. LDH release and DNA
quantification were measured at 24, 48, and 72 h time points (post
final light activation). Control spheroids were also subjected to equal
non-incubation conditions and light fluence rates as spheroids used in
experimental groups.
LDH Release Assay. LDH release was measured in all samples by
collecting 50 μL of media and transferring it to a 96-well plate.
Spheroids which had not been treated with CD-PS conjugates but
which were exposed to equal irradiation times were used as negative
controls for spontaneous LDH release. The positive control was
carried out by incubating spheroids with TE buffer (10 mM Tris−
HCl, 1 mM EDTA, pH 7.5) for 45 min, followed by four freeze-thaw
cycles (frozen 30 min at −80 °C, thawed 10 min at room
temperature) to ensure membrane disruption and indicate maximum
LDH release.
Subsequently, 50 μL of LDH working solution was added to each
well and covered to avoid exposure to light. Plates were incubated for
30 min, and 50 μL of LDH stop solution was added to finalize the
reaction. Briefly, 50 μL of liquid was taken from each well, and
absorbance was read at 490 nm (LDH) and 680 nm (background)
with a microplate reader (Bio Tek Instruments ELx800). Cytotoxicity




% cytotoxicity ((sample LDH release
spontaneous LDH release))
/((maximum LDH release
spontaneous LDH release)) 100
Viability was calculated using the following formula
= −% viability % cytotoxicity % cytotoxicity
control sample
dsDNA Quantification Assay. PicoGreen working solution was
prepared by dissolving the reagent in TE buffer (10 mM Tris−HCl, 1
mM EDTA, pH 7.5) according to the instructions from the
manufacturer. Spheroids were removed from each well and placed
in a 96-well plate and carefully washed three times with 50 μL of
sterile phosphate-buffered saline (PBS) to remove cellular debris. Cell
Figure 1. CD-PS dark toxicity in spheroids is similar, based on relative drug content. CD-PS samples decreased drug-induced cytotoxicity up to 72
h after incubation. LDH release showed CD conjugates caused less damage to the cell membrane compared to PpIX, with some variation in DNA
content at concentrations of 1−10 μg/mL (A). PpIX-adjusted values (PpIX μg/mL) based on the estimated drug content for each sample type
demonstrate no variation regardless of concentration (B). Significance was calculated between CD-PS samples and PpIX in identical treatment
conditions, where *p < 0.05. (N = 3, n = 6).
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lysis was performed by adding 50 μL of TE buffer to each well and
freeze-thawed four times, as detailed previously. An equivalent volume
of 100 μL PicoGreen working solution was added. The plates were
covered from light and incubated for 10 min at room temperature.
Fluorescence was read at 485 nm excitation and 528 nm emission
with a fluorescence plate reader (Bio Tek Instruments FLx800). A
blank was prepared by adding deionized water and PicoGreen in equal
volumes. % dsDNA was calculated with the following formula
= −
×
% dsDNA ((sample dsDNA control dsDNA))
/control dsDNA) 100
Light Microscopy (LM). Images were obtained using an AE2000
inverted light microscope (Motic) fitted with a Moticam 2.0 camera
(2 MP) and a 4× objective. Images were obtained before and after
clearing cellular debris from each well. White balance was optimized
to increase spheroid contrast against the background.
Light Sheet Fluorescence Microscopy (LSFM). Prior to
imaging, the spheroids were fixed with 3.7% paraformaldehyde and
embedded in 1% 2-hydroxyethylagarose. LSFM was carried out with a
ZEISS Lightsheet Z.1 microscope (ZEISS, United Kingdom) fitted
with a W Plan-Apochromat 10× objective. Images were obtained as
Z-stacks with a 1.8 μm slice interval and a stack size of 878.09 μm ×
878.09 μm. Light sheet thickness was adjusted to 6.4 μm, and the
pixel size was 0.46 μm.
Image processing was carried out using ZEISS ZEN 2014 SP1
software version 9.2.0.0 and ImageJ. The image acquisition settings
(excitation/emission wavelengths and other adjustments) for live/
dead microscopy and drug uptake analysis are described in detail
below.
Live/Dead Microscopy. Cells were stained with 2 μM calcein
AM reagent and 4 μM ethidium homodimer-1 to differentiate live and
dead cells. Staining solutions were prepared on the day of use to avoid
the spontaneous hydrolysis of calcein AM due to moisture. Spheroids
were moved to new wells and gently washed with PBS before adding
100 μL of staining solution. The plates were left at room temperature
for 45 min before washing with PBS and storing at 4 °C.
LSFM was carried out with the following: a 405/488/561/640 nm
laser blocking filter, an SBS 560 nm long-pass filter. Images were
captured simultaneously: Calcein AM (detected in the 505−545 nm
range using a bandpass filter) and ethidium homodimer-1 (detected
above 660 nm using a long-pass filter). A 448 nm laser was used at
0.6% power with 119.85 ms exposure time for both fluorophores.
Each spheroid was imaged at 0, 120, and 240° with the same
parameters.
Drug Uptake Analysis. After a 3 h uptake period, the spheroids
were fixed with 3.7% paraformaldehyde and embedded within 1% 2-
hydroxyethylagarose. LSFM was carried out with the following: a
405/488/561/640 nm laser blocking filter, an SBS 560 nm long-pass
filter. A 405 nm laser (5% power and 199.7 μs exposure time) was
used to acquire images. Fluorescence intensity was measured within
the innermost section of the spheroid as determined by Z-stacks (2
μm interval).
Scanning Electron Microscopy (SEM). Spheroids fixed in 3.7%
paraformaldehyde, as described above, were washed twice in PBS at
intervals of 10 min. Afterward, they were fixed a second time in 1%
aqueous osmium tetroxide for 1 h at room temperature before
Figure 2. PDT screening was carried out after incubation with CD-PS conjugates. (a) Treatment efficiency was evaluated using a combination of
microscopy and in vitro assays. (b) Spheroid growth varies according to initial seeding density and impacts PDT evaluation as spheroids
progressively become rounder and larger after the initial 3-day growth period. Spheroids are not affected by 405 nm light and prolonged exposure
outside incubation conditions. (c) PDT conditions for spheroids were tested by comparing control spheroids (no light, placed within normal
incubation conditions) to samples placed outside the incubator (no light, 1 h) and samples exposed to a 405 nm LED light (2.76 mW/cm2, 10 J/
cm2). (N = 3, n = 6). The characteristic quasi-spherical morphology attained during spheroid growth was slightly affected by environmental stress,
seen as debris surrounding the main aggregate indicated with arrows.
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undergoing two more PBS washes. Samples were exposed to an
ethanol series at room temperature at 15 min intervals (75, 95, 100,
100% dried over anhydrous copper sulfate). Each sample was placed
in a 50/50 mixture of 100% ethanol/100% hexamethyldisilazane for
30 min, followed by 30 min in 100% hexamethyldisilazane. Spheroids
were air-dried overnight in a fume-hood and coated with gold in an
Edwards S150B sputter coater. SEM micrographs were obtained using
TESCAN Vega 3 LMU scanning electron microscope at an
accelerating voltage of 20 kV.
Statistical Analysis. Experiments were carried out with three
independent repeats in sextuplicate (N = 3, n = 6), and results were
normalized against untreated control spheroids. Statistical analysis was
done using GraphPad Prism version 8.3.0. Results obtained from
biological assays (LDH and dsDNA quantification) from spheroids in
identical conditions were evaluated by 2-way ANOVA analysis with
Dunnett’s test for multiple comparisons, with adjusted p values < 0.05
considered statistically significant. Data are presented as means ±
standard deviation (SD).
■ RESULTS
In Vitro Evaluation of Dark Toxicity in Spheroids. Cell
culture and scheduling of PDT treatment were optimized such
that the spheroids were treated when they contained a
proliferative rim and small necrotic core and were in the
growth phase. We utilized previously reported PpIX-based
nanoparticle conjugates to evaluate the PDT response in
spheroids compared to cell monolayers, based on a pre-
established concentration range of 1−10 μg/mL.5
As can be seen in Figure 1, conjugation slightly reduces dark
toxicity (approx. 20%), as evidenced by LHD release and
dsDNA content after adjusting for PpIX concentration. This
was only observed at higher concentrations (>5 μg/mL), with
the spheroids recovering after 48 h of incubation. Drug
concentration was also adjusted based on relative drug content
in each sample from the previous characterization and
expressed as PpIX μg/mL (Supporting Table S1). Dark
Figure 3. Fractionated PDT improves PDT effectiveness using lower fluence rates and concentrations. Phototoxicity was evaluated 24 h after
exposure using LDH release and total dsDNA content. Light treatment combinations (1LT and 2LT) were compared based on total fluence (2.5−
10 J/cm2) using equal PS concentrations (μg/mL). Control spheroids were subjected to the same conditions and used to indicate normal spheroid
response. Data was normalized using the negative control (no light, no drug) as 100% and total spheroid disruption as 0%. Significance was
calculated between 1LT and 2LT conditions at equal concentrations, where *p < 0.05. (N = 3, n = 6).
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toxicity showed similar drops in both assays as drug
concentrations were increased, which were considered as
PDT parameters were selected.
In Vitro Evaluation of Phototoxicity in Spheroids.
Phototoxicity in spheroids was evaluated with variations in
fluence and drug doses. The maximum light dose was selected
by examining LDH release, dsDNA content, and spheroid
morphology, following both a single fraction (1LT) and double
fraction (2LT) exposure with untreated spheroids (Figure 2).
Spheroids did not show a significant difference after exposure
to non-incubation conditions or light exposure for periods of
up to 1 h. Spheroids were consequently incubated with PSs
and exposed to increasing doses of light, up to 10 J/cm2. Cell
death can be observed as a halo of debris surrounding the
spheroid, which changes in abundance depending on the
degree of damage sustained after PDT (Supporting Figure S1).
Growth media was replaced to slowly remove debris from each
well, though this became more difficult with increasing
damage, with some spheroids breaking upon rinsing. Low
conjugate doses (1 μg/mL) combined with low fluence (2.5 J/
cm2) showed a limited PDT effect.
The increase of both conjugate concentration and irradiance
increased photoinduced damage, though there was increased
resistance to compound toxicity as spheroids treated with 2.5
J/cm2 (1LT) did not show a significant difference from
nonirradiated spheroids. PpIX-CD consistently outperformed
the other samples at most conditions, though this was only
observed at 24 and 48 h post PDT. Spheroid damage could be
observed up to 72 h after the last light treatment (Supporting
Figures S2 and S3). PpIX@CD showed poor effectiveness at 1
μg/mL for LDH release but demonstrated an equal effect to
both PpIX-CD and PpIX during DNA quantification. PpIX-
loaded conjugates were able to provoke a similar degree of
damage in spheroids compared to PpIX in both assays.
There was a significant difference in observed viability values
derived by LDH release and DNA concentration at low light
doses and drug concentrations (Figure 3). LDH values (%
viability) were significantly different between 1LT and 2LT,
regardless of the sample or treatment conditions. In contrast,
the total dsDNA exhibits no significant change, particularly at
2.5 J/cm2 and 1−5 μg/mL. 1LT was unable to consistently
reduce spheroid viability and DNA content below the 50%
threshold, though high drug/light combinations (1LT with >5
μg/mL and 5 J/cm2) were shown to be significantly more
effective compared to low doses. Fractionated PDT showed a
slight variation between light doses: while LDH release is
significantly higher in fractionated treatments, this was not
always observed with dsDNA quantification. Some variations
can be seen at higher concentrations (>5 μg/mL) or light
exposure (>5 J/cm2). Nonetheless, PpIX and conjugates do
not show a significantly different PDT effect at equal
concentrations and light doses (Supporting Figure S4).
Subsequently, we compared the total radiant exposure in
equivalent treatments, e.g., a single 5 J/cm2 exposure versus a
double fractionated 2.5 J/cm2 exposure (Figure 4). In total, 54
parameter combinations were evaluated using MCTS at three
distinct time points, showing variations in spheroid viability
according to treatments (Supporting, Table S2). LDH release
was significantly affected by sequential exposures, with all
conditions showing improvement over single light treatments
regardless of fluence, concentration, and sample type. In
contrast, dsDNA quantification showed minimal differences
between treatments. Single light treatments (1LT) proved to
be unreliable unless higher drug concentrations were added,
which increased sample variation due to dark toxicity from
samples. Fractionated treatments (2LT) were shown to be
slightly more effective at lower drug concentrations.
PpIX-adjusted values reveal similar results to those
previously observed in cell monolayers. PS concentrations
higher than 1 μg/mL produce greater spheroid damage in both
1LT and 2LT conditions using 41−48% PpIX. In combination
with the previously shown dark toxicity data, these results can
be used to rapidly contrast all treatment conditions to select
suitable combinations for further evaluation. As can be seen in
Figure 4, 1LT treatments showed poor PDT effectiveness
regardless of fluence, concentration, and sample type. While
higher-end single light exposure conditions (5−10 μg/mL, 10
J/cm2) can cross the 80% viability threshold, they are
unsuitable as these PS concentrations already cause up to
25% drops in viability due to dark toxicity. In contrast, 2LT
treatment combinations generally produced much greater
damage across all parameters, with only 1 μg/mL conditions
showing similar results to 1LT. Similarly, high PS concen-
trations were not found to be suitable due to dark toxicity,
indicating a drug dose around 5 μg/mL combined with >2.5 J/
cm2 (2LT) is the most suitable treatment condition for
producing a greater PDT effect while limiting the impact of PS
toxicity.
Quantification of Conjugate Uptake. Light sheet
fluorescence microscopy was used to estimate drug uptake in
spheroids. Spheroids showed some autofluorescence at 405 nm
excitation, though a 560 nm long-pass filter ensured that the
control did not show any appreciable fluorescence emission
after 600 nm. Conversely, spheroids incubated with all samples
and doses (1−10 μg/mL) for 3 h showed clear emission peaks.
Low sample concentrations (1 μg/mL) resulted in uptake
within the spheroid periphery. In contrast, PpIX@CD showed
aggregation within one side of the outermost layer of the
spheroid and low emission in the other areas (Figure 5). The
adjustment of concentration to 5 μg/mL corresponds to a
considerable increase of fluorescence from all samples. PpIX-
CD displayed markedly higher emissions in comparison to the
Figure 4. Summary of PDT parameter screening by treatment
effectiveness. Lower values (green) indicate greater damage to
spheroids after light exposure.
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control PpIX, with approximately 28% more uptake. PpIX-CD
also showed similar values along the innermost part of the
spheroid. In comparison, PpIX@CD continued to show much
lower PpIX accumulation, with only 49−60% emission in
comparison to PpIX and PpIX-CD, indicating possible self-
quenching due to its cargo (Supporting Table S3). The
embedded conjugate once again showed higher uptake in one
side of the spheroid, with drastically reduced emissions on the
opposite sides. This behavior continued as conjugate
concentration increased to 10 μg/mL, though emissions
were only increased 2-fold, compared to 10-fold between 1
and 5 μg/mL.
Observation of PDT-Induced Damage in Spheroids.
The distribution of live/dead cells within MCTS was observed
using LSFM (Figure 5 and Supporting Figure S6). Spheroid
morphology appeared to remain intact from initial viewing
angles, though changes in viewing angles demonstrated the
extent of PDT-induced damage. Imaging shows treated
spheroids have reduced size and slightly irregular morphology
but generally keep their roundness regardless of light
treatment, as shown previously. Images were obtained from
three separate angles to observe morphology after PDT with 5
J/cm2, which was a light dose, which produced significant
damage to the spheroids while reducing time spent outside the
incubator. Drug doses (1−10 μg/mL) and fractionated light
exposures (1LT and 2LT) were left unchanged from the
previous methodology. Samples using 1 μg/mL did not show
significant changes to roundness, with only small sections
being affected, regardless of light dose. Nonetheless, sample
rotation revealed changes in spheroid thickness, which was
reduced from ∼450 to ∼400 μm because of PDT-induced cell
death.
PDT with a concentration of 5 μg/mL significantly
increased damage to the spheroids and caused disruption in
their spherical shape. PpIX and PpIX-CD show damage
throughout the spheroid surface, appearing as large grooves
that run across its diameter and missing sections corresponding
to the area which was in contact with light. The core area of all
spheroids showed a high number of dead cells, which
corresponds to the hypoxic region formed during initial
growth and compaction. The spheroid shape was also
influenced by sample manipulation during fixing and
mounting, as samples frequently needed to be swapped as
too much force caused the spheroids to begin falling apart. In
Figure 5. Spheroids show directional damage to their morphology after PDT. (a) Post-PDT morphology varies according to viewing angle,
showing significant cell death throughout their structure after 24 h. (b) Increased drug doses destabilize spheroid morphology and cause ongoing
cell death after 24 h of PDT (5 J/cm2, 2LT, 10 μg/mL), with further cell death observed up to 48 h after the second light treatment. Initial damage
was like that found in 1LT (middle) and continued to reduce spheroid size while increasing cell death (bottom). (c) Drug uptake in spheroids
varies by sample type and concentration. CD-PS conjugate internalization within spheroids was observed using the middlemost Z-stack image
obtained with light sheet fluorescence microscopy. Relative PpIX concentration is shown as fluorescence intensity across the innermost spheroid
region (∼260 μm depth). Spheroids were incubated with conjugates for 3 h and fixed prior to imaging.
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comparison, spheroids treated with 10 μg/mL show more
pronounced damage and a similar loss of shape and roundness.
However, it should be noted that not all spheroids within the
same conditions showed the same degree of damage.
SEM imaging has been used to observe fine details in
spheroid morphology, revealing cell−cell interactions and
growth progression with higher magnifications. We used
surface morphology as an indicator of morphological changes
not immediately apparent after observation with LM. Control
spheroids show a clear round morphology reminiscent of
images obtained with LM, with few defects on their surface. In
contrast, PDT-treated spheroids show clear deformation after
treatment as ROS production and subsequent cell death
changes spheroid morphology. The previously described
surface sloughing and deformation can be seen in the
representative images shown in Figure 6.
■ DISCUSSION
The development of a spheroid-based model for PDT is
difficult due to variability during the initial stages of growth
and the wide variety of available assays for biological
assessment, which hinder standardization. PDT is highly
dependent on PS concentration, tissue penetration, and oxygen
availability. The first step was to determine the ideal spheroid
size to screen treatment conditions. Spheroids under 200 μm
typically have proliferating and quiescent cells, while those
around 300 μm begin to show signs of hypoxia in their centers.
Furthermore, the diffusion limit of molecules such as oxygen is
150−200 μm, leading to the formation of a necrotic core
within 4−10 days, depending on cell type and initial seeding
density. Therefore, we made use of larger spheroids (>500
μm), which have a higher degree of similarity to murine
xenografts in cell cycle and apoptosis (Supporting Figure
S1).30 Additionally, they have also shown increased drug
resistance in comparison to smaller aggregates (<300 μm)
through a combination of necrosis and hypoxia.31 Dark toxicity
was not found to be substantially different in spheroids after
adjusting concentrations based on relative drug content
(Figure 1). Our results are similar to those reported by
Pereira et al. (2017), who determined that tetraglycosylated
porphyrin PorGlu4 had no significant difference in monolayers
versus spheroids up to 9 μM (5 μg/mL).26
The evaluation of PDT parameters with spheroids required
us to adjust previous fluence values from those used in
monolayers. Previous experiments showed up to a 50%
reduction in metabolic activity in C8161 monolayers treated
with 1 μg/mL PpIX at 0.83 J/cm2 at 405 nm. Conjugates
showed similar results with monolayers: PpIX-CD (LD50
1.9 μg/mL) and PpIX@CD (LD501.6 μg/mL).10 In
contrast, spheroids did not respond to the previous
experimental conditions until fluence was increased to 2.5 J/
cm2. Thus, the fluence range was set to the range of 2.5−10 J/
cm2. While 405 nm light is of limited utility in clinical
applications due to poor tissue penetration, there are some
benefits to its use for research on the choice of illumination
parameters. Helander et al. (2014) demonstrated that using
blue light (410 nm) to carry out PDT with hexyl 5-
aminolevulinate was better than red light (624 nm) at
producing cell death in various cancer cell lines, though red
light induced more apoptosis, highlighting the importance of
evaluating sublethal light doses in PDT.32
Total light exposure remained within the ultralow fluence
range previously utilized by Matthews et al. (2009) to deliver
sublethal light doses to human glioma spheroids with ALA at
1.5−6 J/cm2.33 We were able to use a reliable low-cost
alternative in LEDs, which have shown clinical success with
PDT at various fluence rates.34 An additional benefit of low-
fluence light exposure is the reduction of photobleaching
during treatment, and the LED did not show a significant effect
on spheroid viability up to a 1 h exposure (Figure 2). While PS
fluorescence after exposure to 20 J/cm2 in LSFM (10 J/cm2,
2LT), it is still possible that some photobleaching occurred,
regardless of the decreased fluence. The increase of irradiation
time with a similar light source has also been shown to be
suitable for in vitro PDT evaluation by Raza et al. (2020) in
C8161 spheroids up to 3 h outside incubation conditions
without adverse effects.35
PDT treatments tend toward high fluence values in the
clinic, such as those for ALA (30−540 J/cm2, >100 mW/cm2)
due to increased 1O2 production.
36 However, this process is
highly inefficient as oxygen is rapidly depleted during at least
Figure 6. Standard C8161 melanoma spheroid imaged using SEM. SEM micrographs were taken at 500× magnification. Control spheroids show
some slight damage (visible in the top right corner of the image) due to manipulation during fixation. PDT-treated spheroids underwent directed
light-activated damage after exposure to light. Images correspond to spheroids treated with 5 μg/mL conjugates, 1LT/2LT, 24 h after exposure.
The effect of PDT can be seen as sloughing of outer cell layers increased due to increased damage from 1LT and 2LT PDT.
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40% of the total treatment duration.37 High light intensity
(mW/cm2) causes rapid PS photobleaching, defined as the
point at which ∼37% of fluorescence signal strength is lost.38
PpIX bleaching has been reported to vary, depending on the
intensity of the light source, ranging from 5−150 mW/cm2 (50
J/cm2) in a mouse skin model treated with ALA.39 In
comparison, lower power (∼30 mW/cm2) has been shown to
be equally effective at disrupting tumor growth while
maintaining singlet oxygen production.40 It is possible that
oxygen depletion and subsequent hypoxia in the treated area
may limit further PS activation as the concentration of
immediately available O2 is rapidly diminished after irradiation.
Cells with low PS concentration or insufficient light exposure
have been shown to have minimal PDT-induced death, even
with high fluence (360 J/cm2, 200 mW/cm2).41 The variations
between these treatments could be due to steady PS bleaching
due to a high-intensity light source, effectively reducing its
effective concentration until oxygen consumption could keep
up with available molecules in the tumor microenvironment.
Seshadri et al. evaluated the effectiveness of PDT with high
(100 mW) and low (7 mW) laser power regimens while
adjusting PS concentrations. They did not observe a significant
change in the total area of necrosis after PDT, observing
intermittent hypoxia at 100 mW, ultimately leading to reduced
effectiveness compared to 7 mW.42 This suggests that light
delivery over extended periods of time with lower power
improves PDT effectiveness.
The experimental conditions which were used in the present
study paralleled those reported by Ouyang et al., where
conditions were selected based on the ratio of early apoptotic
to necrotic cells, corresponding to 4 μg/mL PpIX and 5 J/
cm2.43 Similarly, Zawacka-Pankau et al. showed 1 μg/mL PpIX
(2 J/cm2) caused a significant increase in p53-mediated and
independent apoptosis in cancer cells through the activation of
the HDM2-p53 complex.44 In comparison to necrosis,
apoptosis is generally thought to occur within a period of
12−24 h after signaling, though the exact duration is hard to
determine as it depends on the activation pathway.45 The
structural and biological changes that spheroids undergo after
PDT suggest that low-fluence PDT is capable of tumor
destruction at nontoxic PS doses (<5 μg/mL). Debris is a dark
halo surrounding the spheroid consisting of apoptotic and
dead cells, which begins forming immediately after light
exposure (Supporting Figure S3). Sustained damage to
spheroids was also observed in all conditions, reflecting
previous results, where spheroid viability was reduced for up
to 72 h after PDT (Figure 3, Supporting Figures S2 and S3).
While these conditions showed the best results (e.g., 10 μg/mL
at 10 J/cm2, 1LT), it is worth noting that the influence of dark
toxicity increases with higher PS concentrations (>5 μg/mL),
which could misrepresent the efficiency of treatment
conditions using 10 μg/mL PS as viability, and dsDNA
content could be reduced up to ∼20% before PDT.
Light fractionation in PDT has been proposed as a method
for improving treatment outcomes without requiring the use of
longer timescales for irradiation or higher drug doses, enabling
reoxygenation while maintaining PS function and p preventing
photobleaching.46 This method has shown positive results in
preclinical trials, with 2-fold illumination treatments showing a
markedly improved complete response rate compared to the
control.15 Our results showed that 2LT conditions were
significantly more effective than single treatments at most
experimental conditions during the evaluation of LDH release
(Figure 3). In contrast, dsDNA quantification did not
consistently show a significant difference between 1LT and
2LT, suggesting there are other factors which influence PDT
efficiency because of light fractionation. Babilas et al. stated
that fractionated PDT using PpIX (25-−100 mW/cm2) was
less effective compared to single-dose treatments, possibly as a
result of the 15 min interval between light doses.47 Thus, we
increased the time to a 24 h period, allowing reoxygenation
and apoptosis to occur. Similar results were found by de Bruijn
et al. using methyl-5-aminolevulinate (MAL) in a mouse skin
model.16 Their work suggests PS localization before PDT is a
key factor for both treatment effectiveness and determining the
differences between single and multiple light doses.
Inefficient accumulation was shown to greatly diminish PDT
effectiveness regardless of the total energy applied. de Bruijn et
al. later observed PSs responded differently to light
fractionation, suggesting sublethal damage to affected cells
makes them more vulnerable to damage during the following
treatments and highlighting the need for a more comprehen-
sive evaluation of multiple PDT parameters.48 The comparison
between 1LT and 2LT shows a significant difference with LDH
release, in contrast with dsDNA content, which is similar
between treatments. This discrepancy may be influenced by
the death of the proliferating outer cell layer during the first
light treatment, which is followed by recruitment from viable
quiescent cells located within the second spheroid layer.
Proliferating cells are particularly susceptible to PDT due to
their high uptake and oxygenation compared to inner
sections.31 Samples also showed variation in uptake, with
PpIX and PpIX-CD demonstrating penetration within the
spheroid core after incubation, while PpIX@CD mostly
accumulated in the outer layers. Millard et al. demonstrated
the importance of carriers in their use of extracellular vesicles
(EVs) for delivering liposomal meta-tetra(hydroxyphenyl)-
chlorin (mTHPC). When loaded in EVs, mTHPC showed
improved penetration in a cancer spheroid model after 24 h. In
contrast, nonloaded mTHPC showed poor penetration
regardless of incubation time, concentrating in the spheroid
periphery.49
The evaluation of drug uptake and localization within
spheroids is key to obtaining insight into the behavior of PSs
with various treatment combinations, as PDT efficiency is tied
to not only the light dose but also drug concentration and
localization. High uptake within the spheroids is desirable as it
generally leads to enhanced phototoxicity, while inefficient
accumulation results in low ROS production and higher cell
survival. The main challenges associated with microscopy of
spheroids are deformation or disruption before sectioning,
light scattering, and low spatial resolution.50 Light sheet
fluorescence microscopy (LSFM) has been shown to be
capable of analyzing spheroids up to 1 mm in diameter and
determining drug penetration.51 Our data shows drug uptake
was significantly impacted by concentration, coinciding with
previous reports using porphyrins.26 Spheroids exhibited
significantly increased resistance to PDT, possibly due to
slower cell proliferation and uneven PS distribution. This can
be observed within most observed spheroid samples as
fluorescence emissions rapidly decrease after 100 μm within
the samples (Figure 5). Sample type also impacted the uptake,
possibly due to aggregation during the incubation period. In
contrast, cell monolayers typically exhibit uniform oxygen
levels and PS uptake centered near the nuclei.10
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The live/dead staining showed a high level of photoinduced
damage on the outer spheroid layer and disruption of the
spheroid structure with most conditions. The extent of damage
was more apparent with the passage of time, with continuous
loss of sphericity and diameter reduction observed in all
spheroids up to 48 h after treatment. However, the decrease in
spheroid size was not uniform among samples and showed
variation, depending on the viewing angle. The visualization of
damage using multiple viewing angles greatly improved the
post-PDT assessment of treatment efficiency, showing large
sections of spheroids having been sloughed off after PDT.
Spheroids with single light exposures showed a significant
reduction in thickness, with one side displaying high cell death
and deformation as indicated by ethidium homodimer-1
staining, while the other showed more live cells, indicating
that the PDT effect was mostly localized toward the side that
faced the LED.
Spheroid damage after PDT can also be observed by the
changes in surface roughness, which can indicate the amount
of deposited extracellular matrix.52 The outer layers of
spheroids appear to have been sloughed off and have not
been reformed after 48 h post light exposure. This shedding
has been observed in spheroids which have passed their
stationary phase and is considered the start of their death
phase.53 Spheroids treated with 2LT showed a much more
pronounced reduction in size and a higher degree of cell death
than those with 1LT. This was expected as both LDH release
and DNA content indicate lower sample viability with repeat
light exposure. In summary, LSFM and SEM were able to show
clear morphological changes after light activation. Spheroid
thickness was consistently reduced with all samples and
concentrations, though differential drug uptake may cause
variation between samples with identical treatment conditions.
■ CONCLUSIONS
Currently, the gold standard for cancer drug testing is the in
vivo tumor xenograft mouse model, which accurately replicates
most tumor morphophysiological characteristics. However,
animal models are not suitable for exploring the effect of
individual treatment conditions due to their intrinsic complex-
ity. Furthermore, large-scale screening experiments are costly,
time-consuming, and face issues with ethical concerns. In this
study, a total of 18 combinations of different PDT parameters
(drug concentration, fluence, and light fractionation) were
tested with two porphyrin functionalized carbon dot
formulations (PpIX-CD, PpIX@CD) and compared to non-
bound porphyrin (PpIX) totaling 54 combinations. These
treatment conditions were evaluated using two different assays
to determine the viability after PDT (LDH release and dsDNA
quantification) and monitored at three time points (24, 48, and
72 h post-PDT). This led to the prescreening of unsuccessful
PDT conditions such as 1 μg/mL drug doses or 1LT, which
would not have been apparent with only two-dimensional
(2D) cell culture. Fractionated treatments (2LT) were shown
to be significantly more effective compared to single treatments
(1LT) regardless of other parameters. Furthermore, light sheet
microscopy was used to obtain information regarding drug
penetration into spheroids, with PpIX and PpIX-CD showing
higher uptake compared to PpIX@CD. Spheroid morphology
was also shown to be irregular due to varying response to
PDT-induced damage, resulting in the shedding of the outer
proliferating cell layer, which continued up to 48 h post-PDT.
In conclusion, PDT parameter prescreening was able to rule
out multiple previously successful conditions with cell
monolayers. The results presented herein highlight the
importance of custom models tailored for PDT and the
advantages of spheroids as a tool for screening treatment
combinations to evaluate novel compounds.
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